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ABSTRACT
Objective: To determine the long-term effect of
adalimumab on patients with ankylosing spondylitis (AS)
who participated in the Adalimumab Trial Evaluating Long-
Term Efficacy and Safety in AS (ATLAS), a randomised,
double-blind, placebo controlled, 24-week trial.
Methods: Patients received adalimumab 40 mg every
other week (eow) or placebo for 24 weeks in ATLAS. At
week 24, patients were switched to open-label adalimu-
mab 40 mg eow. Efficacy measures included 20%
improvement in the Assessment in SpondyloArthritis
International Society (ASAS) criteria (ASAS20), ASAS40
and ASAS partial remission responses and changes in
individual components of the ASAS20 response evalua-
tions, for example, Bath AS Functional Index (BASFI) and
Bath AS Disease Activity Index (BASDAI). Two-year
interim data were analysed based on the total duration of
adalimumab exposure, irrespective of the treatment
randomisation group.
Results: At 2 years, 255 (82.0%) of the original 311
ATLAS patients continued receiving adalimumab treat-
ment. Improvements in ASAS responses observed in
ATLAS were sustained during long-term treatment; 64.5%
(200/310) were ASAS20 responders, 50.6% (157/310)
were ASAS40 responders and 33.5% (104/310) had
maintained ASAS-defined partial remission. Changes in
individual ASAS response components were sustained or
improved during long-term adalimumab treatment. From
ATLAS baseline to 2 years of adalimumab exposure,
respectively, BASDAI improved from 6.3 (SD 1.7) to 2.4
(SD 2.3) and BASFI improved from 5.2 (SD 2.4) to 2.9 (SD
2.5). Adalimumab was well tolerated. No cases of
tuberculosis, congestive heart failure, lupus-like symp-
toms, or demyelinating disease were reported.
Conclusions: Adalimumab reduced the signs and
symptoms of AS and induced partial remission for up to
2 years. The long-term safety profile was similar to the
short-term safety profile.
Trial registration information: NCT00085644
Ankylosing spondylitis (AS) is a chronic, progres-
sive inflammatory disease that primarily affects the
spine and sacroiliac joints. The onset of AS is
typically in the third decade of life. AS has a
standardised prevalence rate of 0.55% among white
patients
1 and is linked with HLA-B27 positivity.
2
Patients with AS can experience significant long-
term functional impairment and disability, with
reduced quality of life and an increased risk
of comorbid conditions. AS is associated with
significant direct and indirect costs to the patient
and the healthcare system.
3
The essential role of tumour necrosis factor
(TNF) in AS has been shown by the efficacy of
TNF blockade in the treatment of AS. The efficacy
of TNF antagonists, adalimumab, etanercept and
infliximab, has been demonstrated in short-term
clinical studies,
4–10 as well as in long-term studies of
etanercept (up to 2 years)
11 12 and infliximab (up to
3 years).
13–15
The Adalimumab Trial Evaluating Long-term
Efficacy and Safety for AS (ATLAS) demonstrated
that adalimumab, a fully human anti-TNF mono-
clonal antibody, improves the signs and symptoms
of AS for up to 24 weeks and is generally well
tolerated.
16 During short-term treatment, adalimu-
mab also improved the health-related quality of life
(HRQoL) and physical function of patients with
AS.
17 In addition, adalimumab reduced pain,
fatigue and stiffness, three of the most common
concerns of patients with AS.
18 Patients completing
the 24-week, placebo controlled, double-blind
portion of ATLAS were eligible for enrollment in
an open-label extension study (which is still
ongoing) designed to determine the safety and
efficacy of adalimumab treatment in patients with
active AS and the impact of adalimumab on
HRQoL during up to 4.5 years of treatment.
Herein, we report the 2-year interim results of this
open-label extension study.
METHODS
Patients
Patients were 18 years of age or older, diagnosed
with definitive AS based on the modified New York
criteria
19 and fulfilling at least two of the following
three criteria: (1) Bath AS Disease Activity Index
(BASDAI) score 4 or greater; (2) morning stiffness
for 1 h or longer and (3) visual analogue scale (VAS)
score fortotal back pain4 or greater on a scale of 0 to
10. Patients also had an inadequate response to at
least one non-steroidal anti-inflammatory drug and
may(butwerenotrequiredto)havefailedtreatment
with at least one disease-modifying antirheumatic
drug. Additional inclusion and exclusion criteria
have been published previously.
16
Study design
Detailed efficacy, HRQoL and safety methods for
the first 24-week period of the ATLAS study
have been published previously.
16 17 Patients were
randomly assigned in a 2 : 1 ratio to receive either a
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Laboratories, Abbott Park, Illinois, USA) 40 mg every other
week (eow) or matching placebo during the initial 24-week,
randomised, double-blind, placebo controlled period. Based on
evaluation by the investigator, patients who did not achieve at
least a 20% response according to the Assessment in
SpondyloArthritis International Society (ASAS) criteria for
improvement (ASAS20) at double-blind weeks 12, 16, or 20
had the following three options: (1) continue blinded study
medication to week 24; (2) receive early-escape therapy (ie,
open-label adalimumab 40 mg eow before week 24); or (3)
discontinue from the study. Patients who did not achieve an
ASAS20 response after 12 weeks or more of open-label treat-
ment may have been treated with adalimumab 40 mg every
week. The 24-week, double-blind study period was followed by
an open-label extension phase, during which all patients
received adalimumab 40 mg eow or weekly for up to an
additional 4.5 years. Clinic visits occurred every 6 weeks
through the double-blind period and then at weeks 30, 40, 52,
64, 76, 88 and 104.
Measures
The primary efficacy assessment in the randomised, controlled
portion of ATLAS was the ASAS20.
20 The ASAS40, ASAS 5/6,
and ASAS-defined partial remission responses
21 were also
evaluated. For the determination of ASAS 5/6 responses, C-
reactive protein (CRP) concentrations were used as the acute
phase reactant and the Bath AS Metrology Index (BASMI) was
used as the metrology assessment.
22 Additional efficacy end-
points for ATLAS were previously described in detail
16 and
included the patient’s global assessment of disease activity
during the past week, represented by the score on a 0–10 cm
horizontal VAS; pain, as represented by the total back pain
score on a 0–10 cm VAS; the Bath AS Functional Index (BASFI)
score (0–10 cm VAS);
23 inflammation, as determined by the
mean of the severity and duration of morning stiffness based on
0–10 cm VAS scores (mean of questions 5 and 6 of the
BASDAI);
24 the BASMI score (0–10); CRP concentrations;
BASDAI 50 response; and enthesitis, as assessed by the
Maastricht AS Enthesitis Score (MASES; range 0–13).
25
HRQoL measures were also completed at baseline, at weeks
12 and 24
17 and after 1 and 2 years of adalimumab exposure, and
included the AS Quality of Life (ASQoL) questionnaire
26 as well
as the Short Form 36 Health Survey (SF-36). The ASQoL is a
disease-specific instrument designed to measure HRQoL in
patients with AS and has 18 yes or no questions with a total
score of 0–18. Lower ASQoL scores represent a better AS-specific
HRQoL, and a reduction of at least 1.8 points was defined a
priori as the minimum clinically important difference (MCID).
Patients completed the SF-36 version 1 based on a 4-week recall
period.
27 Differences of 3.0 or more points in the SF-36 physical
component summary (PCS) or mental component summary
(MCS) exceed the a priori definition for MCID and are
considered to be clinically meaningful. Adverse events (AE),
vital signs, physical examinations and laboratory assessments
were routinely evaluated.
Statistical analysis
The data cutoff for the 2-year interim analysis of the open-label
extension of ATLAS occurred 2 years after the last patient’s first
visit in the study (that is, the start of the double-blind period).
Data are reported based on adalimumab exposure for each
patient, which was defined beginning with the first dose of
adalimumab administered either during the double-blind period
or the open-label period of the study. Because some patients
were treated with placebo for the first 24 weeks of the study,
not all patients had 2 years of exposure to adalimumab at the
time of this analysis. If a patient received placebo during the
double-blind period of ATLAS, efficacy and HRQoL data
collected during that period were not included in this analysis
of the efficacy of long-term adalimumab treatment. Only
efficacy data collected following a patient’s first dose of
adalimumab are presented. For all efficacy and HRQoL
measures, baseline for all analyses was defined as the last
observation before the first dose of adalimumab. Efficacy results
presented for the 2-year open-label extension are presented as
observed data for all patients who received at least one dose of
adalimumab; last observation carried forward (LOCF) analyses
are also presented for all patients who received at least one dose
of adalimumab. Safety assessments were based on observed data
reported following any adalimumab exposure.
RESULTS
Patient enrollment and disposition
The data for this study were collected between 27 January 2004
and 10 July 2006. Of the 315 patients enrolled in the double-blind
period, 208 were randomly assigned to receive adalimumab 40 mg
Figure 1 Assessment in Ankylosing Spondylitis International Working
Group (ASAS) responses by duration of adalimumab treatment. (A)
Observed data. (B) Last observation carried forward (LOCF) data
(N = 311).
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weekdouble-blind period.
16 At baseline of the double-blind period,
the mean BASDAI scores for both placebo and adalimumab
groupswere6.3(SD1.7).Ofthe311patientswhoreceivedatleast
onedoseofadalimumab(eitherduring the randomised,controlled
portion of ATLAS or during the open-label extension), 261
(83.9%) were receiving adalimumab treatment in the open-label
extension study at the time this analysis was completed.
Demographic and clinical characteristics
Patients were primarily male (74.9%), white (96.1%), and HLA-
B27 positive (78.8%). The mean patient age was 42.3 years (SD
11.56, range 18–71). The mean duration of disease was
11.0 years (SD 9.5, range 0.1–48.4). Baseline clinical character-
istics for the randomised, double-blind study
16 and the current
extension study are displayed in table 1.
Adalimumab exposure
Of the 311 patients who received at least one dose of
adalimumab, median exposure to adalimumab was 2 years
(range 14–896 days). Seventy per cent of patients (218/311)
received adalimumab for at least 1.75 years. Seventy-two
(23.2%) patients who were ASAS20 non-responders in the
randomised, controlled portion of the study switched to
adalimumab 40 mg weekly. Of these 72 patients, 53 had
received weekly treatment for at least 1 year and two had
received weekly adalimumab for 2 years at the time of this
analysis.
Long-term efficacy
Treatment with adalimumab significantly reduced the signs and
symptoms of AS at weeks 12 and 24. The magnitude of
improvement was sustained through 2 years of adalimumab
exposure (fig 1A and B). The percentage of patients achieving
ASAS20, ASAS40, ASAS 5/6 and ASAS partial remission
responses was sustained from week 24 to up to 2 years of
adalimumab exposure (fig 1A and B). During short-term
treatment (24 weeks of adalimumab exposure), 65.2% (202/
310) of patients were ASAS20 responders, 46.1% (143/310) were
ASAS40 responders, 58.6% (181/309) were ASAS 5/6 responders
and 24.2% (75/310) achieved ASAS partial remission based on
LOCF analyses (fig 1B). During long-term treatment (2 years of
adalimumab exposure), 64.5% (200/310) patients were ASAS20
responders, 50.6% (157/310) were ASAS40 responders, 58.9%
(182/309) were ASAS 5/6 responders and 33.5% (104/310)
achieved ASAS partial remission based on LOCF analyses
(fig 1B). Improvements in the individual components of the
ASAS20 response evaluations were also sustained during long-
term adalimumab treatment (table 1).
Mean values for baseline demographics and clinical character-
istics for patients who switched from adalimumab 40 mg eow
to 40 mg weekly were similar to mean values for the overall
group of patients who received adalimumab 40 mg eow
throughout (table 2), with a tendency to a somewhat greater
level of disease activity at baseline. After 6 weeks of weekly
adalimumab therapy, 14 of 61 (23.0%) patients had an ASAS20
response, six of 61 (9.8%) patients had an ASAS40 response and
eight of 61 (13.1%) had a BASDAI 50 response. After 1 year of
receiving adalimumab 40 mg weekly, 18 of 53 patients (34.0%)
achieved an ASAS20 response, eight of 53 (15.1%) achieved an
ASAS40 response and eight of 53 (15.1%) achieved a BASDAI 50
response (observed data); these 53 patients were ASAS non-
responders before being switched to weekly adalimumab
treatment.
Improvements in mean BASDAI scores were sustained for up
to 2 years (table 1). At least a 50% improvement on the BASDAI
was attained by 43.8% (133/304) of patients after 3 months of
adalimumab exposure; 53.8% (157/292) after 6 months; 60.5%
(167/276) after 1 year and 70.5% (122/173) after 2 years
(observed data). Based on LOCF analysis, a BASDAI 50 response
was attained by 42.9% (133/310) of patients after 3 months of
adalimumab exposure; 51.3% (159/310) after 6 months; 55.8%
(173/310) after 1 year and 58.7% (182/310) after 2 years.
Improvements in the signs and symptoms of AS were
sustained during long-term adalimumab treatment (table 1).
Significant reductions in CRP concentrations were sustained
through 2 years of treatment. The statistically significant
improvement in enthesitis (as measured by the MASES)
observed during the 24-week portion of ATLAS continued to
improve during 2 years of adalimumab treatment. The observed
mean change in the MASES was a 3.0 point reduction after
24 weeks of adalimumab treatment compared with a 3.8 point
Table 2 Baseline demographic and clinical characteristics for patients who switched to weekly adalimumab
treatment and patients who received adalimumab 40 mg every other week*
Characteristic
Adalimumab 40 mg
weekly
(N = 72)
Adalimumab 40 mg
every other week
(N = 239)
Male, n (%) 46 (63.9) 187 (78.2)
White, n (%) 69 (95.8) 230 (96.2)
Age, years (SD) 46.1 (10.0) 41.2 (11.8)
Disease duration, years (SD) 10.7 (9.0) 11.1 (9.6)
HLA-B27 positive, n (%) 52 (72.2) 193 (80.8)
Patient’s global assessment of disease activity, cm (SD) 7.0 (2.1) 6.2 (2.1)
Total back pain, cm (SD) 7.2 (2.0) 6.3 (2.1)
Inflammation (mean of questions 5 and 6 of the BASDAI), cm (SD) 7.3 (1.9) 6.5 (2.0)
BASFI, cm (SD) 6.1 (2.3) 5.2 (2.1)
BASDAI, cm (SD) 6.9 (1.6) 6.1 (1.7)
C-reactive protein, mg/dl (SD){ 1.5 (1.6) 2.0 (2.7)
BASMI, 0–10 (SD) 4.5 (2.1) 3.8 (2.2)
Chest expansion, cm (SD) 2.9 (1.5) 3.4 (1.9)
MASES, 0–13 (SD) 8.4 (7.6) 5.9 (6.7)
*Values are mean (SD) unless otherwise noted. {Normal range using an ultrasensitive C-reactive protein assay is 0.007–0.49 mg/
dl. BASDAI, Bath Ankylosing Spondylitis Disease activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath
Ankylosing Spondylitis Metrology Index; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score.
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Ann Rheum Dis 2009;68:922–929. doi:10.1136/ard.2007.087270 925reduction after 2 years of adalimumab treatment. Long-term
adalimumab treatment was also associated with maintenance
of an improvement in spinal metrology, as shown by a decrease
in mean BASMI scores over time (table 1). The improvement in
the overall BASMI score was driven by statistically significant
improvements in three of five components of the BASMI score
(eg, lumbar side flexion, cervical rotation and intermalleolar
distance; p,0.05 for each) at week 24 of the double-blind
portion of the study in adalimumab compared with placebo-
treated patients.
16 The tragus-to-wall and anterior lumbar
flexion components did not respond to adalimumab treatment.
Similarly, chest expansion did not change significantly in
adalimumab-treated patients.
Long-term HRQoL
Changes over time in HRQoL assessments are summarised in
table 3. Improvements based on the ASQoL were substantial
and statistically significant compared with placebo by week 24
and steadily improved over time. The magnitude of improve-
ment was more than twice the prespecified MCID of at least 1.8
points at every time point measured. Improvements in the SF-
36 PCS score were substantial and exceeded the MCID of 3
points for up to 2 years of adalimumab treatment. Although the
change from baseline in SF-36 MCS scores was not statistically
significantly different from placebo at week 24, the mean
improvement in SF-36 MCS scores also exceeded the MCID for
up to 2 years of adalimumab treatment. The mean changes in
SF-36 MCS scores were smaller in magnitude than the
improvements in the SF-36 PCS and were stable over time.
Safety
Overall, adalimumab was well tolerated. The safety profile
during long-term treatment was consistent with that observed
during short-term treatment.
16 During up to 2 years of
adalimumab exposure, the most common AE (reported by
>5% of patients) were nasopharyngitis, upper respiratory tract
infection and headache (table 4). For the patients treated with
adalimumab during the double-blind period and then during the
open-label period, respectively, the following AE rates per 100
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Table 4 Adverse events reported by 5% or more of patients during up
to 2 years of adalimumab treatment
Adverse event
Adalimumab
(N = 311)
n (%)
Nasopharyngitis 80 (25.7)
Upper respiratory tract infection 53 (17.0)
Headache 48 (15.4)
Arthralgia 33 (10.6)
Sinusitis 30 (9.6)
Fatigue 25 (8.0)
Diarrhoea 30 (9.6)
Nausea 27 (8.7)
Influenza 23 (7.4)
Cough 26 (8.4)
Back pain 23 (7.4)
Hypertension 23 (7.4)
Pharyngolaryngeal pain 22 (7.1)
Bronchitis 20 (6.4)
Viral infection 19 (6.1)
Injection-site reaction 15 (4.8)
Pharyngitis 19 (6.1)
Rash 17 (5.5)
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serious infectious AE, 0 versus 1.1; AE leading to discontinua-
tion, 3.8 versus 4.5 and malignant AE, 0.0 versus 0.9.
The numbers and percentages of patients who experienced
TNF-associated AE of interest are summarised in table 5. There
were no cases of tuberculosis, congestive heart failure, lupus-like
symptoms, or demyelinating disease and no deaths were
reported. There were six serious infectious AE (1.9% of
patients). Of these, three were considered possibly or probably
related to the study drug. One patient (0.3%) had an
adalimumab-related hypersensitivity reaction. Weekly adminis-
tration of adalimumab did not cause any additional safety issues
(table 4).
Malignancies occurred in four patients (1.3%). One patient, a
56-year-old man, was diagnosed with non-Hodgkin lymphoma
after 176 days of treatment. The non-Hodgkin lymphoma was
considered by the investigator to be possibly related to the study
drug. The patient was discontinued from the study and
observed by his oncologist. The patient’s lymph nodes regressed
without chemotherapy and the patient did not require any
treatment at last contact. The other three cases of malignancies
included two cases of non-melanoma skin cancer (one case of
squamous-cell carcinoma and one case of basal-cell carcinoma)
and one case of malignant melanoma. All three patients were
treated by surgical excision of the affected site.
Of the 311 patients who received at least one dose of
adalimumab, 94 had a history of uveitis, seven had a history of
Crohn’s disease and 10 had a history of ulcerative colitis. Twelve
of 311 (3.9%) patients developed uveitis during follow-up. Of
these 12, three had new-onset uveitis and nine patients
experienced flares. One patient with a history of ulcerative
colitis had a flare of ulcerative colitis. One patient with no
previous history of inflammatory bowel disease developed
Crohn’s disease. None of the patients with a history of
Crohn’s disease experienced a flare.
There were no clinically meaningful changes in clinical
chemistry values, liver enzymes, or vital signs during long-term
adalimumab exposure.
DISCUSSION
The placebo-controlled portion of ATLAS demonstrated that
adalimumab treatment improves the signs and symptoms of AS
for up to 24 weeks, beginning within 2 weeks of treatment.
16
ATLAS is the largest long-term study of a TNF antagonist for
the treatment of active AS, with 255 patients continuing
adalimumab treatment at the time of this 2-year analysis. The
BASDAI 50, ASAS20, ASAS40, ASAS 5/6 and ASAS partial
remission responses that were achieved during the initial 24-
week, double-blind period of ATLAS were sustained for up to
2 years of treatment. Improvements in individual components
of the ASAS response (patient’s global assessment of disease
activity, pain, function and inflammation) were also sustained
for up to 2 years of adalimumab treatment.
The progressive restriction in spinal mobility experienced by
patients with AS contributes to significant functional disability
and reduced HRQoL. Adalimumab treatment led to sustained
improvements in physical function and mobility during long-
term treatment. After 2 years of adalimumab treatment, 75% of
patients experienced a sustained improvement in BASMI. Not
all assessments of spinal mobility that were evaluated in the
ATLAS trial demonstrated a significant difference between the
treatment groups. However, it is known that the tragus-to-wall,
anterior lumbar flexion and chest expansion are, in general, not
very responsive measures, especially not in established disease.
Table 5 Summary of TNF-associated AE of interest during up to 2 years of adalimumab treatment
Adverse event
Adalimumab exposure
Weekly
(N = 72)
n (%)
Any
(N = 311)
n (%)
Any
(PY = 533.7)
AE/100 PY
Any AE 62 (86.1) 293 (94.2) 445.6
At least possibly drug-related AE 31 (43.1) 174 (55.9) 107.7
Serious AE 5 (6.9) 48 (15.4) 10.5
At least possibly drug-related serious AE 0 17 (5.5) 3.7
AE leading to discontinuation of study drug 1 (1.4) 24 (7.7) 4.5
Infectious AE 37 (51.4) 213 (68.5) 109.7
Serious infectious AE 1 (1.4) 6 (1.9) 1.1
Appendicitis 0 1 (0.3) 0.2
Bacteraemia 0 1 (0.3) 0.2
Beta-haemolytic streptococcal infection 1 (1.4) 1 (0.3) 0.2
Cellulitis* 0 1 (0.3) 0.2
Pneumonia{ 0 1 (0.3) 0.2
Rectal abscess{ 0 1 (0.3) 0.2
Drug hypersensitivity-related AE 0 1 (0.3) 0.4
Malignancies 1 (1.4) 4 (1.3) 0.7
Basal-cell carcinoma 0 1 (0.3) 0.2
Malignant melanoma 1 (1.4) 1 (0.3) 0.2
Non-Hodgkin’s lymphoma 0 1 (0.3) 0.2
Squamous cell carcinoma of the skin 0 1 (0.3) 0.2
Injection-site reactions 2 (2.8) 42 (13.5) 17.6
Opportunistic infections{ 0 4 (1.3) 0.7
Tuberculosis 0 0 0
Demyelinating disease 0 0 0
Deaths 0 0 0
*Possibly related to adalimumab treatment. {Probably related to adalimumab treatment. {All four cases were oral candidiasis. AE,
adverse event; PY, patient-years; TNF, tumour necrosis factor.
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that patients experienced at week 24 in the randomised,
controlled portion of ATLAS increased in magnitude through
1 and 2 years of adalimumab treatment.
In addition, long-term adalimumab treatment was associated
with improved HRQoL as demonstrated by substantial and
sustained improvements assessed using a disease-specific mea-
sure (ASQoL). The improvements in SF-36 PCS scores demon-
strated that adalimumab treatment is associated with an
improvement in physical HRQoL that exceeded the MCID
and increased over time. These HRQoL results are consistent
with long-term studies of etanercept
11 and infliximab.
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The ASAS20, ASAS40 and BASDAI 50 response rates after
1 year of weekly adalimumab therapy indicate that increasing
the dosage of adalimumab may benefit some patients and may
be considered before switching to an alternative therapy.
Adalimumab was generally well tolerated during up to
2 years of treatment. There were no unexpected safety concerns
during this long-term study. Of note, patients with AS who
received weekly adalimumab treatment did not experience a
higher rate of AE compared with patients who received
treatment eow. The overall safety profile of adalimumab is
similar to other anti-TNF therapies used for the treatment of
AS,
7 9 11 12 28 and is consistent with the safety profile of
adalimumab during long-term treatment of patients with
rheumatoid arthritis or psoriatic arthritis.
29–34
CONCLUSIONS
Adalimumab treatment for up to 2 years reduced the signs and
symptoms of AS and induced a partial remission. The
substantial improvements in spinal mobility and enthesitis that
were observed in ATLAS continued to increase during long-term
therapy. The HRQoL of patients with active AS was also
substantially improved during long-term adalimumab treat-
ment. Adalimumab was generally well tolerated; the long-term
safety profile was similar to the short-term safety profile.
Continued evaluation of these patients will further define the
long-term safety and efficacy profile of adalimumab for the
treatment of patients with active AS.
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